The estimated Net Worth of Lloyd Carney is at least $37.4 Millón dollars as of 26 April 2024. Mr. Carney owns over 909 units of Vertex Pharmaceuticals stock worth over $1,230,051 and over the last 19 years he sold VRTX stock worth over $35,717,526. In addition, he makes $494,534 as Independent Director at Vertex Pharmaceuticals.
lloyd has made over 36 trades of the Vertex Pharmaceuticals stock since 2007, according to the Form 4 filled with the SEC. Most recently he sold 909 units of VRTX stock worth $250,475 on 26 April 2024.
The largest trade he's ever made was selling 1,050,916 units of Vertex Pharmaceuticals stock on 22 March 2017 worth over $13,104,923. On average, lloyd trades about 73,386 units every 84 days since 2006. As of 26 April 2024 he still owns at least 2,591 units of Vertex Pharmaceuticals stock.
You can see the complete history of Mr. Carney stock trades at the bottom of the page.
Lloyd A. Carney is Independent Director of the Company. Mr. Carney is the Chairman and Chief Executive Officer of ChaSerg Technology Acquisition Corp., a technology acquisition company. He was the Chief Executive Officer of Brocade Communications Systems Inc., or Brocade, a global supplier of networking hardware and software, from January 2013 until 2017, when it was acquired by Broadcom. Prior to Brocade, he served as Chief Executive Officer of Xsigo Systems, a cloud-based infrastructure solutions provider, until its acquisition by Oracle. He has also served as the Chief Executive Officer and Chairman of Micromuse Inc., a software solutions provider for business and service assurance, until its acquisition by IBM. Earlier in his career he had held senior leadership roles at Juniper Networks, Inc., Nortel Networks Inc., and Bay Networks, Inc. He currently sits on the board of directors at Visa Inc. and Nuance Communications, Inc. He holds a Bachelor of Science degree in Electrical Engineering Technology from Wentworth Institute, a Master of Science degree in Applied Business Management from Lesley College, and an Honorary Doctorate degree in Engineering from Wentworth Institute.
As the Independent Director of Vertex Pharmaceuticals, the total compensation of lloyd Carney at Vertex Pharmaceuticals is $494,534. There are 20 executives at Vertex Pharmaceuticals getting paid more, with Jeffrey Leiden having the highest compensation of $18,790,000.
lloyd Carney is 57, he's been the Independent Director of Vertex Pharmaceuticals since 2019. There are 7 older and 17 younger executives at Vertex Pharmaceuticals. The oldest executive at Vertex Pharmaceuticals, Inc. is William Young, 75, who is the Independent Director.
Lloyd's mailing address filed with the SEC is C/O VERTEX PHARMACEUTICALS INCORPORATED, 50 NORTHERN AVENUE, BOSTON, MA, 02210.
Over the last 21 years, insiders at Vertex Pharmaceuticals have traded over $934,925,905 worth of Vertex Pharmaceuticals stock and bought 308,652 units worth $12,298,449 . The most active insiders traders include Lloyd Carney, Jeffrey M Leiden y Joshua S Boger. On average, Vertex Pharmaceuticals executives and independent directors trade stock every 5 days with the average trade being worth of $4,747,875. The most recent stock trade was executed by Jeffrey M Leiden on 30 August 2024, trading 3,784 units of VRTX stock currently worth $1,888,216.
Vertex Pharmaceuticals is an American biopharmaceutical company based in Boston, Massachusetts. It was one of the first biotech firms to use an explicit strategy of rational drug design rather than combinatorial chemistry.
Vertex Pharmaceuticals executives and other stock owners filed with the SEC include: